Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FiREBOLT phase 1a/1b study of LY4337713 in FAP-positive solid tumors
jRCT2031260614Phase 1Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2026
- Modality
- Peptides
01
Overview
Phase 1, open-label trial of retatrutide in pancreatic adenocarcinoma (PDAC), breast cancer, ovarian cancer and 5 more (6 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Dose-limiting toxicity and Objective response rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)breast cancerovarian cancergastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031260614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260614.